What genetic mutations are commonly found in Colorectal Cancer

Common Genetic Mutations in Colorectal Cancer

Colorectal cancer (CRC) involves several important genetic mutations that doctors test for because they directly affect treatment options and prognosis. Let me walk you through the most significant ones.

The Major Mutations Doctors Test For

RAS Mutations (KRAS and NRAS)

These are among the most common mutations found in colorectal cancer. According to the NCCN Guidelines for Colon Cancer, all patients with metastatic (advanced) CRC should be tested for KRAS and NRAS mutations as part of their initial workup.

Why it matters: If your tumor has a KRAS or NRAS mutation, you cannot be treated with certain targeted antibody drugs called cetuximab or panitumumab—these medications only work when the KRAS and NRAS genes are wild-type (normal). This is a critical finding because it changes your treatment options significantly.

BRAF Mutations

BRAF mutations occur in a smaller percentage of colorectal cancers, but they're very important to identify.

Key points:

• BRAF V600E (the most common BRAF mutation) makes response to cetuximab or panitumumab highly unlikely unless these drugs are combined with a BRAF inhibitor
• BRAF mutations are also a strong prognostic marker—meaning they tell us something about how the cancer may behave. According to NCCN Guidelines, patients with BRAF-mutant tumors generally have worse overall survival compared to those with wild-type BRAF
• BRAF mutations are often associated with proximal (right-sided) colon cancers, poor differentiation, and more advanced disease at diagnosis

HER2 Amplification/Overexpression

HER2 is a growth-promoting protein that's rarely amplified in CRC (about 3% overall), but it's more common in tumors that are wild-type for RAS and BRAF (5-14%).

Clinical significance: According to NCCN Guidelines, all patients with metastatic CRC should be tested for HER2 amplification. If present, HER2-targeted therapies like trastuzumab (Herceptin) combined with other drugs become treatment options.

---

Mismatch Repair (MMR) and Microsatellite Instability (MSI)

What These Mean

Mismatch repair genes (MLH1, MSH2, MSH6, PMS2) normally act like "spell-checkers" for DNA, catching and fixing errors during cell division. When these genes don't work properly (called deficient mismatch repair or dMMR), errors accumulate, creating what's called microsatellite instability (MSI-H).

Universal testing recommendation: The NCCN Guidelines strongly recommend that all newly diagnosed patients with colon cancer receive MMR or MSI testing, regardless of family history. This is important for:

• Identifying Lynch syndrome (hereditary colorectal cancer)
• Guiding treatment decisions
• Determining if immunotherapy checkpoint inhibitors might be beneficial

Why It Matters for Treatment

Patients with MSI-H/dMMR tumors often respond very well to checkpoint inhibitor immunotherapy drugs like pembrolizumab or nivolumab, which help the immune system recognize and attack cancer cells.

---

Less Common But Important Mutations

POLE/POLD1 Mutations

These genes encode "proofreading" proteins that fix DNA copying errors. When mutated, they create an ultra-hypermutated phenotype—meaning the tumor has an extremely high number of mutations.

Key findings from NCCN Guidelines:

• Somatic POLE mutations occur in 2-8% of colorectal cancers
• Patients with POLE/POLD1 mutations have a more favorable prognosis and respond well to checkpoint inhibitor immunotherapy
• These mutations create many neoantigens (tumor-specific targets) that the immune system can recognize

NTRK Fusions

These are extremely rare in CRC (about 0.35% of cases) and are found almost exclusively in tumors that are wild-type for KRAS, NRAS, and BRAF.

Treatment implication: NTRK inhibitors are FDA-approved for patients whose tumors have NTRK fusions.

RET Fusions

RET fusions activate a growth-promoting pathway in cancer cells. The FDA-approved drug selpercatinib targets RET fusions in solid tumors, including colorectal cancer.

---

Why Testing Matters: The Clinical Framework

Here's how doctors think about these mutations:

1. Predictive markers tell us which treatments will work (e.g., "KRAS wild-type = can use cetuximab")
2. Prognostic markers tell us about cancer behavior and outcomes (e.g., "BRAF mutation = worse prognosis")
3. Treatment selection depends on the complete molecular profile

According to NCCN Guidelines, testing should be performed on:

• Formalin-fixed paraffin-embedded tissue (preferred) from either the primary tumor or metastasis
• Blood-based assays (increasingly used)
• CLIA-certified laboratories using validated methods

---

Questions to Ask Your Oncologist

If you've been diagnosed with colorectal cancer, consider asking:

1. "Has my tumor been tested for KRAS, NRAS, and BRAF mutations?" (This is standard for metastatic disease)
2. "What was my MMR/MSI status, and what does that mean for my treatment options?"
3. "Were any other mutations found, like HER2, POLE, or NTRK?"
4. "Based on my specific mutations, which treatment approaches do you recommend?"
5. "Are there any clinical trials available for my mutation profile?"

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.